title: Anti-prolactin autoantibodies in pregnant women with systemic lupus erythematosus: maternal and fetal outcome.
abstract: The aim of this study was to determine in pregnant women with systemic lupus erythematosus (SLE) the frequency of anti-prolactin autoantibodies and to compare the outcome of pregnancy in SLE women with and without anti-prolactin autoantibodies. Ninety-nine consecutive SLE pregnant women and 151 healthy pregnant women were studied prospectively. Patients with or without anti-prolactin autoantibodies were identified by gel filtration chromatography and affinity chromatography for IgG. Serum total and free prolactin (PRL) levels and molecular heterogeneity of PRL at each trimester of pregnancy were determined. The frequency of anti-PRL autoantibodies in SLE pregnant women was 13.1%. Serum total PRL levels were significantly higher in women with anti-PRL autoantibodies compared with SLE women without anti-PRL autoantibodies and in healthy pregnant women; and serum free PRL levels were lower in the third trimester in women with anti-PRL autoantibodies than in healthy pregnant women. In contrast, serum total and free PRL levels were significantly lower in the second and third trimester in SLE pregnant women without anti-PRL autoantibodies compared with healthy pregnant women. All adverse outcomes of pregnancy studied were more frequent in SLE women without anti-PRL autoantibodies than anti-PRL autoantibody-positive SLE women. Moreover, both maternal and fetal main complications were significantly higher in SLE women without anti-PRL autoantibodies than anti-PRL autoantibody-positive SLE women (P </=0.03). We conclude that the frequency of anti-PRL autoantibodies in lupus pregnancy was 13.1%. SLE pregnant women with anti-PRL autoantibodies had fewer adverse outcomes of pregnancy. The presence of anti-PRL autoantibodies could be of potential use as a prognostic marker for outcomes of pregnancy in SLE.
authors.affiliation: Research Unit in Reproductive Medicine, Hospital de Ginecología y Obstetricia Luis Castelazo Ayala, Instituto Mexicano del Seguro Social, México, DF, México. alfredolm@yahoo.com
authors.forename: A
authors.initials: A
authors.lastname: Leaños-Miranda
authors.forename: G
authors.initials: G
authors.lastname: Cárdenas-Mondragón
authors.forename: A
authors.initials: A
authors.lastname: Ulloa-Aguirre
authors.forename: I
authors.initials: I
authors.lastname: Isordia-Salas
authors.forename: A
authors.initials: A
authors.lastname: Parra
authors.forename: J
authors.initials: J
authors.lastname: Ramírez-Peredo
mesh_terms: D000022:Abortion, Spontaneous; D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D002846:Chromatography, Affinity; D002850:Chromatography, Gel; D005260:Female; D005333:Fetus; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications* / Q000276:immunology*; D009035:Mothers; D011225:Pre-Eclampsia / Q000097:blood / Q000276:immunology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000276:immunology*; D011256:Pregnancy Outcome; D011388:Prolactin / Q000276:immunology* / Q000302:isolation & purification; D050497:Stillbirth
chemical_list: D001323:Autoantibodies; D011388:Prolactin